Mean change in 6-minute walk distance (6MWD) from baseline to end of study in clinical trials of pulmonary arterial hypertension treated with monotherapy. Epoprostenol, continuous infusion, 12 weeks;24 bosentan, 125 mg, 16 weeks;39 ambrisentan, 10 mg, 12 weeks;26 sitaxentan, 100 mg, 18 weeks;40 sildenafil, 20 mg, 12 weeks;41 tadalafil, 40 mg, 16 weeks.42 Only unadjusted data from active treatment arms are shown.